Taken together, these results suggest that EGFR wild-type, not EGFR mutant NSCLC with inherent resistance to EGFR inhibitors as opposed to acquired resistance, are more likely to show effective tumor inhibition using this combination treatment. Here, EGFR is linked to non-small cell lung carcinoma.